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Abstract
Background: Alcohol consumption is associated with increased risk of breast cancer (BC), and the underlying
mechanism is thought to be sex-hormone driven. In vitro and observational studies suggest a mechanism involving
peroxisome proliferator-activated receptor gamma (PPARγ) in a complex with peroxisome proliferator-activated
receptor gamma coactivator 1-α (PGC-1α) and interaction with aromatase (encoded by CYP19A1). Use of non-steroidal
anti-inflammatory drugs (NSAID) may also affect circulating sex-hormone levels by modifying PPARγ activity.
Methods: In the present study we assessed whether genetic variation in CYP19A1 is associated with risk of BC in a
case-control study group nested within the Danish “Diet, Cancer and Health” cohort (ncases = 687 and ncontrols = 687)
and searched for gene-gene interaction between CYP19A1 and PPARGC1A, and CYP19A1 and PPARG, and gene-alcohol
and gene-NSAID interactions. Association between the CYP19A1 polymorphisms and hormone levels was also
examined among 339 non-HRT users. Incidence rate ratios were calculated based on Cox’ proportional hazards
model. Furthermore, we performed a pilot randomised controlled trial to determine the effect of the PPARG
Pro12Ala polymorphism and the PPARγ stimulator Ibuprofen on sex-hormone levels following alcohol intake in
postmenopausal women (n = 25) using linear regression.
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Results: Genetic variations in CYP19A1 were associated with hormone levels (estrone: Prs11070844 = 0.009, estrone
sulphate: Prs11070844 = 0.01, Prs749292 = 0.004, Prs1062033 = 0.007 and Prs10519297 = 0.03, and sex hormone-binding
globulin (SHBG): Prs3751591 = 0.03) and interacted with alcohol intake in relation to hormone levels (estrone sulphate:
Pinteraction/rs2008691 = 0.02 and Pinteraction/rs1062033= 0.03, and SHBG: Pinteraction/rs11070844 = 0.03). CYP19A1/rs3751591 was both
associated with SHBG levels (P = 0.03) and with risk of BC (Incidence Rate Ratio = 2.12; 95 % Confidence Interval:
1.02–4.43) such that homozygous variant allele carriers had increased levels of serum SHBG and were at increased
risk of BC. Acute intake of alcohol decreased blood estrone (P = <0.0001), estrone sulphate (P = <0.0001), and
SHBG (P = 0.009) levels, whereas Ibuprofen intake and PPARG Pro12Ala genotype had no effect on hormone levels.
Conclusions: Our results suggest that genetically determined variation in CYP19A1 is associated with differences
in sex hormone levels. However, the genetically determined differences in sex hormone levels were not convincingly
associated with BC risk. The results therefore indicate that the genetically determined variation in CYP19A1 contributes
little to BC risk and to alcohol-mediated BC risk.
Trial registration: NCT02463383, June 3, 2015.
Keywords: Alcohol consumption, Breast cancer, Polymorphisms, CYP19A1, PPARG, Female sex-hormones, NSAID,
Prospective nested case-control study, Epidemiology, Randomised controlled trial
Background
Alcohol is a well-known risk factor for breast cancer
(BC) [1–3], and observational studies have shown that
intake of alcohol is associated with 7-10 % increased risk
of BC per 10 g alcohol consumed per day (defined as a
unit of alcohol by the World Health Organisation) [4–9]. It
is believed that at least part of the underlying mechanism
is sex-hormone driven [1, 10, 11]. Several controlled ex-
perimental and observational human studies demonstrate
associations between alcohol intake and increased female
sex-hormone blood concentrations in pre- and post-
menopausal women [12–25]. Additionally, alcohol is
more strongly associated to hormone-sensitive BCs than
hormone-insensitive subtypes [26]. Increased aromatization
[27, 28], impairment of estrogen metabolism in the liver
[27] or stimulation of adrenal steroidogenesis [17] are pos-
sible mechanisms by which alcohol increases sex-hormone
concentrations in women.
Genetic epidemiology in BC research may be used to
elucidate the involved molecular pathways and define
subpopulations of women being more susceptible to
alcohol-related BC risk. Indeed, in the Danish prospect-
ive cohort study “Diet, Cancer and Health” (DCH), vari-
ant allele carriers of the PPARG2 Pro12Ala (rs1801282)
polymorphism had a 20 % increased risk of BC per 10 g
of alcohol consumed per day, whereas carriage of the wild
type allele was not associated with alcohol-related BC [29],
thus implicating peroxisome proliferator-activated receptor
gamma (PPARγ) in alcohol-related breast carcinogenesis.
In an updated study including 798 BC cases, the risk esti-
mate was 13 % increased risk per 10 g alcohol per day
among variant allele carriers [30].
PPARγ is a transcription factor which regulates adipo-
cyte differentiation and expression of several adipocyte
specific genes by binding to regulatory response ele-
ments in target genes as a heterodimer with retinoid X
receptor (RXR) [31]. The Pro to Ala substitution caused
by the single nucleotide polymorphism (SNP), PPARG2
Pro12Ala, is only present in PPARγ2 isoform, which is
primarily expressed in adipose tissue [31]. The PPARG2
Pro12Ala substitution causes a 30 % reduction in target
gene transcription [32]. In postmenopausal women, estro-
gens are primarily synthesized in adipose tissue, where
aromatase (encoded by CYP19A1) catalyses the bio-
synthesis of estrogens [33]. Intake of alcohol increases
aromatase expression in fat tissue in rats [34], and
aromatase is negatively regulated by PPARγ at the
transcriptional level [35, 36] by a mechanism involving
binding of the PPARγ-RXR complex to peroxisome
proliferator-activated receptor gamma coactivator 1-α
(PGC-1α) [37]. An in vitro study has shown that ethanol
inhibits the PPARγ-PGC-1α complex at physiologically
relevant concentrations [30]. Moreover, Petersen et al. also
showed that PGC-1α dependent co-activation of the
PPARγ-complex is compromised for the rare Ala-variant
of PPARG Pro12Ala. Thus, it was proposed that alcohol
inhibits PPARγ-mediated inhibition of aromatase tran-
scription, resulting in an alcohol and PPARγ-dependent
increased aromatase transcription and increased levels of
sex-hormones.
Several commonly used non-steroidal anti-inflammatory
drugs (NSAIDs) including ibuprofen are PPARγ agonists
[38]. Indeed, some NSAIDs are suspected to function as
endocrine disruptors [39, 40]. In the DCH cohort study,
interaction between use of NSAIDs and the PPARG
Pro12Ala polymorphism in relation to alcohol-related risk
of BC was observed [29]. NSAID use did not modify the
risk of alcohol-related BC among PPARG Pro12Ala wild
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type carriers, however, among variant carriers, only users
of NSAIDs were at risk of alcohol-related BC. Thus, the
study indicated that NSAIDs activate the less active
PPARγ 12Ala variant so that it has the same effect as the
wild type PPARγ Pro12 transcription factor. In a meta-
analysis, NSAIDs use has been associated with lowered
risk of BC [41]. However, in the DCH cohort, female
NSAID users, with an intake of more than 13 g alcohol
per day had a 1.60 fold increased risk of BC compared to
non-users of NSAIDs who consumed less than 3 g of alco-
hol per day [42], indicating that alcohol consumption
modifies BC risk among NSAID users.
In the present study we further pursue the proposed
mechanism of action of alcohol-related BC. We assess
whether genetic variation in CYP19A1 is associated with
risk of BC in a case-control study group nested within
the DCH cohort; and search for gene-gene interactions
with CYP19A1 and PPARGC1A, and CYP19A1 and
PPARG, and gene-alcohol and gene-NSAID interactions
(interactions between PPARG and PPARGC1A were ex-
amined and published previously [30]). Association be-
tween the CYP19A1 polymorphisms and hormone levels
is also examined in a cross-sectional study based on the
nested case-control study. Furthermore, we perform a
pilot randomised controlled trial (RCT) to determine the
effect of PPARG Pro12Ala and the PPARγ stimulator,
Ibuprofen [38], on sex-hormone levels following alcohol
intake in postmenopausal women.
Methods
DHC cohort study
Participants
The subjects were selected from the ongoing Danish
DCH cohort study. The present study group has been
described previously [8, 30]. In short, 79,729 women
aged 50–64 years, born in Denmark, living in the
Copenhagen or Aarhus areas and having no previous
cancers at the time of invitation were invited to partici-
pate in the study between December 1993 and May
1997. A total of 29,875 women accepted the invitation,
corresponding to 37 % of the invited women.
Study participants were followed up for diagnosis of
BC from date of entry until either the date of diagnosis
of cancer using record linkage to the Danish Cancer
Registry until 2003 and afterwards by linkage to the Danish
Pathology Databank, date of death, date of emigration, or
April 27th, 2006, whichever came first. A total of 975
women were diagnosed with BC during the follow-up
period. For each case, one matched control was selected [8,
30, 43]. The control was cancer-free at the exact age at
diagnosis of the case and was further matched on age at in-
clusion into the cohort (half-year intervals), use of hormone
replacement therapy (HRT) (current/former/never) and
on certainty of postmenopausal status (known/probably
postmenopausal) upon inclusion into the cohort. “Known”
postmenopausal status was defined as women that were
either: (1) non-hysterectomized and reporting no men-
struation during 12 months before inclusion, (2) reporting
bilateral oophorectomy, or (3) reporting age at last men-
struation lower than age at hysterectomy. “Probably” post-
menopausal status was defined as women that were either:
(1) reporting menstruation during the 12 months prior to
inclusion and current use of HRT (we assumed the bleed-
ing was caused by HRT), (2) reporting hysterectomy with
a unilateral oophorectomy or an oophorectomy of un-
known laterality, or (3) reporting last menstruation at the
same age as age of the hysterectomy operation [8]. 72 indi-
viduals were excluded because of missing information
about one or more of the potential confounding variables.
Additionally 239 individuals were excluded because of
failed genotyping or no buffy coat was available. 265 indi-
viduals were excluded because of a missing partner in the
matched case-control pair, due to the above mentioned
exclusions leaving 687 pairs for data analyses (Fig. 1).
Levels of estrone, estrone sulphate and SHBG were
previously determined for a subset of the DCH study
(434 cases and controls) in plasma samples collected at
entry into the cohort - a cross-sectional study [44]. Of
these 434 cases and controls, 8 had extreme hormone
measures, 117 had missing values on hormone analyses,
genotypes or confounder information, and 404 were
present users of HRT resulting in 339 women for these
analyses.
Data on covariates
From the baseline questionnaires we obtained informa-
tion on duration of school education, smoking status,
HRT use, birth pattern (number of births and age at first
birth) and alcohol intake. Body Mass Index (BMI) was
computed based on measurements of height and weight
at enrolment (kg/m2). Intake of alcohol was inferred
from the food-frequency questionnaire and life-style
questionnaire as described in details in [8, 30]. Ab-
stainers were defined as those who reported no intake of
alcohol on the food-frequency questionnaire and no
drinking occasions on the lifestyle questionnaire. The
lifestyle questionnaire included this question regarding
use of NSAID: Have you taken more than one pain re-
lieving pill per month during the last year? If the answer
was yes, the participant was asked to record how frequent
they took each of the following medications: ‘aspirin’, ‘para-
cetamol’, ‘ibuprofen’, or ‘other pain relievers’. The latter cat-
egory included NSAID preparations other than aspirin
and ibuprofen. Based on all records, we classified study
subjects according to use of ‘any NSAID’ (≥2 pills per
month during one year) at baseline. Findings on all of
these known risk factors have been reported previously for
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both the entire DCH cohort, for a subset of the present
study, and for the present study group [5, 8, 29, 42, 45, 46].
Ethics statement
All participants gave verbal and written informed consent
before enrolment to the study. The Diet, Cancer and
Health study was approved by the National Committee on
Health Research Ethics (journal nr. (KF) 01-345/93), and
the Danish Data Protection Agency.
RCT
Participants
The RCT was conducted at the Department of Nutri-
tion, Exercise and Sports, University of Copenhagen,
Denmark. The participants were recruited by advertise-
ments in the Copenhagen area, in local newspapers and
at the webpage www.forsogsperson.dk. To be eligible,
women had to meet the following requirements: 1) aged
50–70 years and postmenopausal (last menstruation at
least 1 year earlier); 2) having no history of hysterectomy
before last menstruation with preservation of both ovaries
(unless a medical confirmation for the postmenopausal
status exists or the participant is 60 years or older); 3) hav-
ing no major health problems, such as ulcers, heart dis-
eases, diabetes or cancer; 4) having a weekly alcohol use of
less than 14 drinks, but not being an abstainer and having
no history of alcohol abuse; 5) not using HRT; 6) not tak-
ing prescription medications that could interfere with the
study (i.e. daily use of NSAIDs and/or medication that
interact with PPARγ e.g. cholesterol lowering medicine);
7) having a BMI of 18–35; 8) not being allergic to alcohol
and/or Ibuprofen; 9) being a non-smoker.
Power calculation showed that there was an 80 %
chance of finding a 10 % change in estradiol level if 11
participants were included in each group (α = 5 %). In
order to take drop out into account, we decided to enrol
18 women in each group. However, only 7 (16 %) women
were PPARG 12Ala carriers, and they were all included in
the study as well as 18 homozygous wild type carriers of
the PPARG Pro12 allele.
Study design
The study was performed as a randomised, double-
blinded, placebo controlled 2x24 h crossover study as
Fig. 1 Flow chart illustrating inclusion and exclusions of participants in the nested case-control postmenopausal DCH study
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illustrated in Fig. 2. The two interventions were sepa-
rated by a 5–7 week washout period. Alcohol was sup-
plied as 96 % ethanol (Navimer, G.D.C., Jumet, Belgium)
in an 8 % solution with 1:8 Rose’s Lime Flavour Cordial
Mixer® (Dr Pepper Snapple Group Inc., Plano, Texas),
1:8 Rose’s Sugar Cane Flavour Cordial Mixer® (Dr Pepper
Snapple Group Inc., Plano, Texas) and water (0.4 g
ethanol/kg b.w.). Placebo and Ibuprofen tablets looked
identical. Placebo tablets were supplied by The Pharmacy
of the Capital Region of Denmark (Herlev, Denmark), and
Ibuprofen (2 x 200 mg) by Nycomed ApS (Roskilde,
Denmark).
Forty-eight hours before each intervention, participants
were asked to refrain from alcohol consumption and any
form of painkillers. The participants showed up fasting
and were served lunch at the University’s dining facility
1½ hour before drinking (Fig. 3). The lunch consisted of a
sandwich, which was identical for each participant at each
intervention, and was eaten within 30 min. All blood sam-
ples were collected following 10 min supine resting. The
first blood sample was drawn 40 min before serving the
drink. Just after this blood collection and 30 min prior to
drinking, participants had their Ibuprofen or placebo tab-
let administered. This time point was chosen in order to
Fig. 2 Flow chart illustrating inclusion and exclusions of participants in the RCT performed as a randomised, double-blinded, placebo controlled
2x24 h crossover study
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capture the plasma concentration peak of Ibuprofen which
is 1–2 h after administration [47, 48]. After another
30 min, the alcoholic beverage was administered and con-
sumed within 30 min under the surveillance of a research
assistant to ensure that the drink was ingested slowly over
the entire period. After 30, 60 and 90 min, blood was col-
lected. These time points were selected based on two
other studies reporting peak in blood estradiol concentra-
tions between 30 and 60 min after alcohol consumption
[16, 20]. The next morning, the participants showed up
again for the last blood collection. This time point was
chosen to enable the comparison of our results with those
obtained in long term intervention or cohort studies
where blood typically is collected the day after having con-
sumed alcohol. Since estrone sulphate has a half-life of 5–
7 h [17], an alcohol induced change in estrone sulphate
caused by disruption in estrogen biosynthesis would be
measurable in this morning blood sample.
Blood sampling and storage
For the genotype screening, blood was collected in 6 ml
EDTA BD Vacutainer® Blood Collection Tubes (Becton,
Dickinson and Company) and buffy coat was separated
by centrifugation (4000 rpm, 4 °C) and frozen at −80 °C.
During the intervention, blood was collected in 10 ml
silicone-coated serum BD Vacutainer® Blood Collection
Tubes (Becton, Dickinson and Company) for ethanol
and hormone measurements. The tubes were left at room
temperature for >30 min, centrifuged (4000 rpm, 4 °C)
and aliquots were frozen at −80 °C. To avoid ethanol evap-
oration from the tubes during storage, serum for ethanol
analysis was kept in tubes with airtight caps.
Ethics statement
The research protocol was approved by The National
Committee on Health Research Ethics for the Capital
Region of Denmark, protocol number: H-3-2013-056.
All participants received oral and written information
concerning the study before giving their written consent.
Laboratory methods
DCH cohort study
DNA from the DCH participants was extracted from
frozen lymphocytes as described [49]. PPARG Pro12Ala
(rs1801282), PPARGC1A Gly482Ser (rs8192678) and
PPARGC1A Thr612Met (rs3736265) were determined as
previously described [30] and have been published previ-
ously [29, 30]. Ten tagging SNPs of the CYP19A1 gene
were selected using publicly available HapMap [50]
genotyping data set from Utah residents with ancestry
from Northern and Western Europe (CEU, version 3,
release 2) in combination with Haploview (version 4.2,
Broad Institute, Cambridge USA) [51] comprising the
major variations in CYP19A1. Criteria for SNP inclusions
Fig. 3 The study course for each participant at each intervention in
the RCT. The intervention was repeated with or without Ibuprofen
resulting in two interventions per participant
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were a minor allele frequency of minimum 5 % and an r2
threshold of 0.1. Tagging of SNPs with an r2 higher than
0.1 resulted in several SNPs being in complete linkage dis-
equilibrium. Moreover, our intention was to include only
major polymorphisms in the gene. Four polymorphisms
were force included in the aggressive SNP tagging
(rs10046, rs749292, rs1062033 and rs10519297) due to
their documented effect on aromatase RNA expression,
blood hormone levels and/or BC risk [11, 52–59].
Moreover, one of the tag SNPs (rs4646) has been associ-
ated with BC [59] and blood estrogen levels [53, 56, 60];
another tag SNP (rs2445762) was associated with low
estradiol levels in GWAS [61]; and rs3751591 is located
in a recombination spot between two haplotype blocks
(Additional file 1).
Four of the polymorphisms (rs10046, rs749292,
rs1062033 and rs10519297) were determined using the
ABI 7900HT RT-PCR system (Applied Biosystems,
Nærum, Denmark): rs10046 and rs1062033 were deter-
mined using the TaqMan® Pre-designed SNP genotyping;
assay ID C_8234732_30 and C_8794680_30, respectively
(Applied Biosystems, Nærum, Denmark). rs749292:
Primers: F: 5’-GCT TCT GCC AGT CCT TCT TCA-3’,
R: 5’-GCT TAG GGC CTG ATA GAA ATT GTG-3’
(TAGCopenhagen, Copenhagen, Denmark), G-allele:
5’-FAM-CTC GGA GTC GAG GAT-MGB-3’, A-allele:
5’-VIC-TCG GAG TCA AGG ATT-MGB-3’ (Applied
Biosystems, Nærum, Denmark). rs10519297: Primers:
F: 5’CCT TGC CTG AGC CAT CTC TT-3’, R: 5’- CTT
GGC AGT CAA AAG CAG TAG TAG TC-3’ (TAG-
Copenhagen, Copenhagen, Denmark), G-allele: 5’-FAM-
CTC CGA CAT GGG TC-MGB-3’, A-allele: 5’-VIC-TCT
CCG ACA TAG GTC-MGB-3’ (Applied Biosystems,
Nærum, Denmark).
The remaining six CYP19A1 polymorphisms (rs2008691,
rs2445762, rs3751591, rs4646, rs6493487 and rs749292)
were genotyped by KBioscience (KBioscience, Hoddesdon,
United Kingdom) by PCR-based KASP™ genotyping assay
(http://www.lgcgenomics.com/). To confirm reproducibil-
ity, genotyping was repeated for 10 % of the samples yield-
ing 100 % identical genotypes.
Serum levels of estrone, estrone sulphate and sex-
hormone binding globulin (SHBG) were previously de-
termined for a subset of the DCH study (434 cases and
controls) in blood samples collected at entry into the
DCH cohort [44]. Estrone and estrone sulphate were
measured by radioimmunoassay and SHBG by use of
immunofluorometric analysis.
RCT
DNA was isolated from frozen lymphocytes as described
by Miller et al. [49]. Genotypes were determined using
RT-PCR and allelic discrimination on ABI 7900HT in-
struments (Applied Biosystems, Nærum, Denmark).
Generally, 40–200 ng/μl DNA was obtained and 10 ng
of DNA was genotyped in five μl containing 50 % 2 ×
Mastermix (Applied Biosystems, Nærum, Denmark),
100 nM probes, and 900 nM primers. PPARG Pro12Ala
(rs1801282) primers and probes were: primers: 5’-GTT
ATG GGT GAA ACT CTG GGA GAT-3’ and 5’-GTT
ATG GGT GAA ACT CTG GGA GAT-3’: probes: C-
allele: 5’‘-FAM-CTC CTA TTG ACG CAG AAA GCG
ATT C-BHQ-1-3’ and G-allele: 5’-Yakima Yellow-TCC
TAT TGA CCC AGA AAG CGA TTC C-BHQ-1-3’.
Serum ethanol concentration was measured by the en-
zymatic rate assay (kat. no. 11776312190, Roche Diagnos-
tics GmbH, Mannheim, Germany) using the ABX Pentra
400 (Horiba Medical, Brøndby, Denmark) instrument with
inter- and intra assay variations of <4 %. All samples from
each participant were analysed in duplicates in random
order and in the same batch to decrease analytical
variation.
Analyses of estrogens and SHBG levels were per-
formed at the Department of Clinical Biochemistry and
Immunology, Statens Serum Institute, Copenhagen,
Denmark. Estrogens were extracted by Solid-Phase Ex-
traction and the extracts were analyzed using Liquid-
Chromatography (LC) coupled to Mass-Spectrometry
(MS). All samples were analyzed in duplicate and the
average of both measurements was used. Within the
working range of the method (20 pmol/L to 50 nmol/L)
the coefficient of variation (CV) for all analytes were 10 %
for estrone, estrone sulphate and 17β-estradiol and the
CV’s increased below the working range and reached 20 %
at the limit of quantification (LOQ) (10 pmol/L). 60 % of
the estradiol analyses were below the limit of detection
(LOD) (1 pmol/L); therefore, these measurements were
excluded from statistical analyses. SHBG was determined
on an Abbott Architect using Abbotts SHBG kit (Abbott,
Abbott Park, Illinois). The LOD and the intra- and inter-
assay CV were 0.1 nmol/l, 4 and 6 %, respectively.
Statistical methods
DCH cohort study
Deviation from Hardy-Weinberg equilibrium was assessed
using a Chi square test.
The analysis of the association between the exposure
variables and the BC incidence rate ratios (IRR) was
based on a conditional logistic regression analysis corre-
sponding to a Cox Proportional Hazard model due to
the used study design [62]. Age was used as the time
axis. Two-sided 95 % confidence intervals (CI) for the
IRR were calculated on the basis of Wald’s test of the re-
gression parameter, that is, on the log rate ratio scale.
All models were adjusted for baseline values of risk factors
for BC such as parity (entered as two variables; parous/
nulliparous and number of births), age at first birth, length
of school education (low, medium and high), duration of
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HRT use, and BMI. Analyses not concerning interaction
between alcohol intake and the polymorphisms were fur-
ther adjusted for alcohol intake of 10 g per day. For the
different genetic variations, we investigated different inter-
actions with alcohol intake and use of NSAID, using the
likelihood ratio test. IRR was calculated separately for het-
erozygous and homozygous variant allele carriers. For all
the SNPs except for rs3751591, all variant allele carriers
were subsequently grouped for interaction analyses since
no recessive effects were observed. For rs3751591, a re-
cessive mode was used in the subsequent analyses.
Haplotypes of CYP19A1 were inferred manually as done
previously [63–65].
For the analyses with sex-hormone levels as outcome,
multiple log-linear regression analyses of the association
between CYP19A1 genotypes and serum levels of es-
trone, estrone sulphate and SHBG were performed with
adjustment for potential confounders i.e., age (linear),
smoking (categorical: never, past and current) and BMI
(linear). All interaction terms were kept in the models in
all analyses even though there was no interaction for
comparison. All values of hormone concentrations were
log-transformed to correct for left-skewed distribution.
The statistical analyses were carried out using the
PHREG and GLM procedure in SAS (release 9.3, SAS
Institute, Inc, Cary, North Carolina, USA).
RCT
Linear regression was used to evaluate the effect on
PPARG Pro12Ala genotype status and treatment of Ibu-
profen during consumption of alcohol.
Two different models were used to analyse the data
due to non-linear responses with time over the whole
period (0 to 1200 min). Model A only involved the time
at the beginning of the trial period and the end (time = 0
and time = 1200 min), whereas model B involved the
times 0, 30, 60, and 90 min after start. Model A used the
PROC MIXED procedure in SAS with id as the random
effect nested with genotype and order (geno*order). The
explanatory categorical variables were treatment with
Ibuprofen and placebo (treat), order in which they were
given Ibuprofen or placebo (order), genotype (geno), and
time (0 and 1200). BMI was included as a covariate.
Model B also used the PROC MIXED procedure in
SAS with id as the random effect nested with genotype
and order (geno*order). The explanatory categorical vari-
ables were treatment with Ibuprofen or placebo (treat),
order in which they were given Ibuprofen and placebo
(order), genotype (geno), and time (0, 30, 60, 90). BMI
was included as a covariate. Time was also included as
repeated measurement with id (geno*treat*order) as
the subject.
The response variable, estrone sulphate, was log-
transformed to correct for right-skewed distribution.
The response variables estrone, SHBG and ethanol were
not log-transformed, since the conditional residuals were
not or only very little skewed.
In some of the analyses, one or two outliers were re-
moved if they were very dominating, had high Cook’s D
value and a relatively large residual value. Zero values of
estrone measurements (11 %) were replaced by half of
LOD = 0.5 pmol/L.
The statistical analyses were carried out using SAS
(release 9.3, SAS Institute, Inc, Cary, North Carolina,
USA). For all tests, a P value less than 0.05 was consid-
ered statistically significant.
Results
DCH cohort study
Baseline characteristics of the present study group includ-
ing BC risk factors are presented in Table 1 as published
previously [8, 30]. Among the controls, the genotype
distributions of the studied polymorphisms were in
Hardy–Weinberg equilibrium (results not shown).
Associations with hormone levels
The cross-sectional study group including 339 women
from the matched case-control study was used for this
analysis. Among past and never users of HRT, the hor-
mone levels were associated with genotype of five of the
ten studied polymorphisms. Variant T-carriers of the
CYP19A1/rs11070844 polymorphism had 17 % higher
estrone levels (P = 0.009) and 14 % higher estrone
sulphate levels (P = 0.01) than homozygous wild type al-
lele carriers (Table 2). SHBG levels were 37 % higher
among CC-carriers of the CYP19A1/rs3751591 polymor-
phisms compared to T-carriers (P = 0.03). Carriers of the
variant alleles of the two CYP19A1 polymorphisms
rs749292 and rs1062033 had 12 % lower levels of estrone
sulphate compared to homozygous wild type allele car-
riers (P = 0.004 and 0.007, respectively), and variant car-
riers of the CYP19A1/rs10519297 polymorphism had
12 % higher levels of estrone sulphate compared to
the wild type (P = 0.03). Thus, several of the studied
SNPs were associated with hormone levels (Table 2).
Three of the ten CYP19A1 polymorphisms were associ-
ated with alcohol-dependent changes in hormone levels
according to genotype (Table 3). Carriers of the variant al-
leles of CYP19A1/rs2008691 and CYP19A1/rs1062033
polymorphisms had 3 % and 1 % higher estrone sulphate
levels, respectively, compared to homozygous wild type
carriers (P-value for interaction (Pint) = 0.02 and 0.03,
respectively) per 10 g alcohol intake per day. Variant T-
carriers of the CYP19A1/rs11070844 polymorphism
had 3 % lower levels of SHBG compared to the wild
type carriers (Pint = 0.03) per 10 g daily alcohol intake. In
general, estrone and estrone sulphate levels increased
whereas SHBG levels decreased for every 10 g alcohol
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consumed per day irrespectively of genotype (Table 3).
Estrone sulphate levels differed significantly according to
CYP19A1/rs3751591 genotype for NSAID users and non-
users, respectively (Pint = 0.008) (Additional file 2). Car-
riers of the CC genotype had 48 % higher levels of estrone
sulphate when using NSAID compared to T-carriers who
did not use NSAID (95 % CI: 3;114), whereas T-allele car-
riers who were also NSAID users had 13 % decreased
levels of estrone sulphate (95 % CI; −20;-5). However,
these estimates were based on very small numbers. There
was also a borderline statistically significant interaction be-
tween NSAID usage and the CYP19A1/rs6493487 poly-
morphism in relation to SHBG levels (Pint = 0.05). Overall,
NSAID users had higher levels of SHBG and lower levels
of estrone and estrone sulphate (Additional file 2). Thus,
some of the studied CYP19A1 SNPs were associated with
hormone levels and a few other SNPs interacted with
alcohol intake in relation to hormone levels. CYP19A1/
rs1062033 was associated to both hormone levels and
to alcohol-dependent differences in hormone levels.
Associations with BC risk
Homozygous variant carriers of the CYP19A1/rs3751591
polymorphism were at 2.12-fold increased risk of BC (95 %
CI: 1.02-4.43) compared to wild-type carriers (Table 4).
Carriers of the haplotype combination GGG/GAG
(CYP19A1/A-rs10046-G, A-rs6493487-G, A-rs10519297-G)
were at 56 % increased risk of BC (IRR = 1.56; 95 % CI:
1.02-2.40) (Additional file 3). Thus, CYP19A1/rs3751591
was both associated with SHBG levels and with risk of
BC such that homozygous variant allele carriers had
higher levels of serum SHBG and were at increased
risk of BC.
None of the CYP19A1 polymorphisms interacted with
alcohol (Additional file 4) or NSAID usage (Additional
file 5) in relation to BC risk. All risk estimates showed
increased risk of BC of 10-66 % per 10 g alcohol per day
regardless of genotype (Additional file 4). NSAID usage
also increased BC risk compared to non-users irrespec-
tively of genotype (Additional file 5). There was no inter-
action between any of the CYP19A1 polymorphisms and
being carrier of either of the PPARG Pro12Ala alleles
(Additional file 6). However, we found interaction be-
tween CYP19A1/rs3751591 and PPARGC1A Gly482Ser
(Pint = 0.02) in relation to BC risk (Additional file 7); and
interaction between CYP19A1/rs4646 and PPARGC1A
Thr612Met (Pint = 0.002) in relation to BC risk (Additional
file 8). Wild type carriers of CYP19A1/rs4646, who were
also variant Met-carriers of PPARGC1A Thr612Met were
at 2.06-fold increased risk of BC (95 % CI: 1.17-3.65).
Conversely, variant CYP19A1/rs4646-carriers, who also
carry the variant PPARGC1A Thr612Met allele had a
Table 1 Baseline characteristics of the DCH study participants by selected demographic and established BC risk factors
Variable Cases Controls IRRa (95 % CI)
n (%) Median (5–95 %) n (%) Median (5–95 %)
Women 687 (100) 687 (100)
Age at inclusion, years 57 (51–64) 57 (51–64)
School education
Short 198 (29) 257 (37) 1.0 (ref.)
Medium 344 (50) 316 (46) 1.39 (1.07–1.79)
Long 145 (21) 114 (17) 1.59 (1.13–2.24)
Body mass index, kg/m2 25 (20–34) 25 (20–34) 1.01 (0.96–1.07)b
Nulliparous 102 (15) 78 (11) 1.02 (0.64–1.60)c
Number of births 2 (1–4) 2 (1–4) 0.92 (0.79–1.06)
Age at first birth, years 23 (18–31) 23 (18–32) 1.07 (0.91–1.25)d
Use of HRT, yearse 6 (0.5–19) 5 (0.5–20) 1.00 (0.87–1.15)f
Abstainers 15 (2) 22 (3) 0.80 (0.40–1.61)g
Alcohol intake, g/day 11 (1–43) 9 (1–40) 1.12 (1.04–1.21)h
NSAID usei 286 (42) 239 (35) 1.33 (1.07–1.66)
Values are expressed as medians (5th and 95th percentiles) or as fractions (%)
aThe risk estimates for breast cancer are mutually adjusted
bThe risk is estimated per additional 2 kg/m2
cThe risk is estimated for nulliparous versus one birth at age 35
dThe risk is estimated per additional 5 years
eAmong ever users of HRT
fThe risk is estimated per additional 5-year of HRT use
gThe risk for abstainers compared to the increment of 10 g alcohol per day
hAmong drinkers, risk estimate is estimated for the increment of 10 g alcohol per day
i NSAID use is defined as ≥ 2 pills per month during one year
Kopp et al. BMC Cancer  (2016) 16:283 Page 9 of 19
Table 2 Plasma levels of estrone, estrone sulphate and SHBG among 339 never and past users of HRT as percentage difference in
hormonal measurements in relation to CYP19A1 polymorphisms
Genotype n (%) Estrone P-
valueb
Estrone sulphate P-valueb SHBG P-valueb
n = 339 Δ (95 % CI)a Δ (95 % CI)a Δ (95 % CI)a
rs10519297
AA 81 (24) 0 (ref.) 0 (ref.) 0 (ref.)
AG 187 (55) 8 (−4;21) 0.35 10 (−1;21) 0.05 −5 (−14;6) 0.66
GG 71 (21) 1 (−13;16) 16 (3;31) −2 (−14;11)
AG + GG 258 (56) 6 (−6;18) 0.34 12 (1;23) 0.03 −4 (−13;6) 0.44
rs749292
GG 101 (30) 0 (ref.) 0 (ref.) 0 (ref.)
AG 169 (50) −5 (−15;6) 0.62 −11 (−19;-2) 0.007 −3 (−12;7) 0.07
AA 69 (20) −5 (−17;9) −16 (−26;-6) 11 (−2;26)
AG + AA 238 (70) −5 (−14;5) 0.33 −12 (−20;-4) 0.004 1 (−8;11) 0.82
rs1062033
CC 88 (26) 0 (ref.) 0 (ref.) 0 (ref.)
CG 180 (53) −2 (−13;10) 0.53 −10 (−19;-1) 0.01 −1 (−11;9) 0.45
GG 71 (21) −7 (−20;6) −16 (−26;-6) 6 (−7;21)
CG + GG 251 (74) −4 (−14;7) 0.51 −12 (−20;-3) 0.007 1 (−9;11) 0.88
rs10046
AA 93 (27) 0 (ref.) 0 (ref.) 0 (ref.)
AG 177 (52) 2 (−9;15) 0.58 4 (−5;15) 0.26 −1 (−10;10) 0.94
GG 69 (20) −4 (−17;10) 11 (−2;25) −2 (−14;11)
AG + GG 246 (73) 0 (−10;12) 0.93 6 (−3;16) 0.21 −1 (−10;9) 0.82
rs4646
CC 186 (55) 0 (ref.) 0 (ref.) 0 (ref.)
CA 133 (39) 3 (−7;14) 0.68 5 (−3;15) 0.38 −4 (−13;5) 0.59
AA 20 (6) −6 (−23;16) 10 (−8;31) −5 (−21;15)
CA + AA 153 (45) 2 (−8;12) 0.73 6 (−3;15) 0.18 −4 (−13;4) 0.30
rs6493487
AA 203 (60) 0 (ref.) 0 (ref.) 0 (ref.)
GA 127 (38) −5 (−14;5) 0.27 4 (−4;14) 0.63 −5 (−13;4) 0.37
GG 9 (3) −19 (−40;9) 0 (−23;29) −14 (−34;13)
GA + GG 136 (41) −6 (−15;4) 0.23 4 (−4;13) 0.36 −5 (−13;3) 0.22
rs2008691
AA 220 (65) 0 (ref.) 0 (ref.) 0 (ref.)
GA 109 (32) 4 (−6;15) 0.35 3 (−6;12) 0.83 2 (−7;12) 0.17
GG 10 (3) 21 (−9;60) 0 (−21;28) 27 (−1;64)
GA + GG 119 (35) 5 (−4;16) 0.29 2 (−6;12) 0.57 4 (−5;14) 0.37
rs3751591
TT 241 (71) 0 (ref.) 0 (ref.) 0 (ref.)
TC 90 (27) 2 (−9;13) 0.55 1 (−8;10) 0.50 1 (−9;11) 0.09
CC 8 (2) 19 (−13;63) 18 (−10;54) 38 (4;83)
CC vs. TT + TC 8 (2) 18 (−14;62) 0.29 17 (−10;53) 0.24 37 (4;82) 0.03
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38 % decreased risk of BC (IRR = 0.62; 95 % CI: 0.36-
1.08) (Additional file 8). When including alcohol in the
model as 10 g alcohol per day, practically all CYP19A1
polymorphisms interacted with PPARG Pro12Ala (Pint-
values between 0.03-0.10) (Additional file 9). Only
PPARG Pro12Ala wild type carriers were at significantly
increased risk of BC. Neither PPARGC1A Gly482Ser nor
PPARGC1A Thr612Met interacted with any of the
CYP19A1 polymorphisms when inferring the BC risk
per 10 g alcohol per day (Additional files 10 and 11).
There were no interactions with NSAID use for combi-
nations of CYP19A1 genotypes for 10 g alcohol per day
(Additional file 12).
RCT
Baseline characteristics of the study participants are pre-
sented in Table 5, and mean hormone, ethanol and
SHBG concentrations in Additional file 13. Baseline
measurements (time = 0) did not differ between the two
intervention groups (results not shown). Intake of Ibupro-
fen and PPARG Pro12Ala genotype were not associated
with hormone or SHBG concentrations. However, there
was a statistically significant effect of time on hormone
concentrations (model B); that is, estrone, estrone sulphate
and SHBG concentrations declined over the time period
from 0 to 90 min (Pestrone = <0.0001, PSHBG = 0.009 and
Pestrone sulphate = <0.0001) (Figs. 4, 5 and 6), whereas the
ethanol concentration increased as expected (Pethanol =
<0.0001) (Fig. 7). There was no effect of time in model
A on any markers except for estrone concentrations,
which increased at the latest time point (1200 min)
compared to baseline (t = 0) (P = 0.02). BMI was signifi-
cantly associated with concentrations of SHBG (P = 0.02)
and ethanol (P = 0.04), such that women with high BMI
also had higher blood concentrations.
Discussion
In the present study, polymorphisms in CYP19A1 were
associated with circulating blood levels of female sex-
hormones and there was interaction between genotypes
and alcohol consumption in relation to blood levels.
Specifically, CYP19A1/rs1062033 was associated to both
estrone sulphate levels and to alcohol-dependent differ-
ences in estrone sulphate levels. CYP19A1/rs3751591
was both associated with SHBG levels and with risk of
BC such that homozygous variant allele carriers had in-
creased levels of serum SHBG and were at increased risk
of BC. In addition we found indications of interaction
between NSAID use, CYP19A1 polymorphisms and levels
of circulating female sex-hormones. We found that
CYP19A1 polymorphisms interacted with polymorphisms
in PPARGC1A in relation to risk of BC, but there was no
interaction with alcohol intake. Additionally, we showed
that acute alcohol consumption affected circulating blood
hormone and SHBG levels, but Ibuprofen intake and
PPARG Pro12Ala status did not affect the found sex-
hormone concentrations.
In the prospective study, we were able to show that in-
herent variations in CYP19A1 were associated with up
to 24 % differences in female sex-hormone levels, and
CYP19A1/rs3751591 was both associated with SHBG
levels and with risk of BC. CYP19A1/rs3751591 and the
GGG/GAG (CYP19A1/A-rs10046-G, A-rs6493487-G, A-
rs10519297-G) haplotype combination were associated
with BC risk, but these results were based on very low
numbers of cases and should therefore be interpreted
with caution. CYP19A1/rs3751591 has no known func-
tion; it was chosen as a tag SNP and is located in a re-
combination hot spot. However, our results are in
agreement with several other studies showing associ-
ation between CYP19A1 polymorphisms and estrogens
[53, 55, 56, 66], but not BC risk [67–69]. The results
Table 2 Plasma levels of estrone, estrone sulphate and SHBG among 339 never and past users of HRT as percentage difference in
hormonal measurements in relation to CYP19A1 polymorphisms (Continued)
rs2445762
TT 175 (52) 0 (ref.) 0 (ref.) 0 (ref.)
TC 142 (42) −3 (−12;7) 0.71 −1 (−9;8) 0.71 −3 (−19;16) 0.53
CC 22 (6) −7 (−24;13) −7 (−21;10) −5 (−13;4)
TC + CC 164 (48) −3 (−12;6) 0.47 −2 (−10;6) 0.63 −5 (−13;4) 0.27
rs11070844
CC 267 (79) 0 (ref.) 0 (ref.) 0 (ref.)
TC 68 (20) 17 (4;31) 0.03 13 (2;25) 0.04 6 (−5;18) 0.20
TT 4 (1) 16 (−26;79) 23 (−16;79) 36 (−9;103)
TC + TT 72 (21) 17 (4;31) 0.009 14 (3;25) 0.01 7 (−3;19) 0.18
SHBG Sex-hormone binding globulin
Δ Percentage difference in hormonal measurements compared to WT
aAdjusted for age, smoking (never, past, current), alcohol intake (increment of 10 g per day) and BMI (kg/m2) at baseline
bP-value for trend
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Table 3 Plasma levels of estrone, estrone sulphate and SHBG among 325 never and past users of HRT, who were also current
drinkers, as percentage difference in hormonal measurements per 10 g/day in alcohol intake
Genotype n (%) Estrone P-valueb Estrone sulphate P-valueb SHBG P-valueb
n = 325 Δ (95 % CI)a Δ (95 % CI)a Δ (95 % CI)a
rs10519297
AA 74 (23) 2 (−4;9) 3 (−3;9) −5 (−11;0)
AG 182 (56) 3 (−1;6) 0.82 3 (0;7) 0.17 −6 (−9;-3) 0.23
GG 69 (21) 1 (−5;6) 4 (0;9) −3 (−7;2)
AG + GG 251 (77) 2 (−1;5) 0.54 4 (1;6) 0.08 −5 (−8;-2) 0.27
rs749292
GG 98 (30) 3 (−2;7) 4 (1;8) −5 (−8;-1)
AG 165 (51) 1 (−3;6) 0.96 3 (0;7) 0.38 −6 (−9;-2) 0.94
AA 62 (19) 2 (−5;10) −1 (−7;6) 0 (−7;6)
AG + AA 227 (70) 1 (−2;5) 0.85 3 (−1;6) 0.15 −5 (−8;-1) 0.95
rs1062033
CC 86 (26) 1 (−3;6) 4 (0;8) −5 (−9;-1)
CG 175 (54) 3 (−1;7) 0.76 4 (0;7) 0.11 −5 (−8;-2) 0.67
GG 64 (20) 1 (−6;8) 1 (−4;7) −4 (−9;2)
CG + GG 239 (74) 2 (−1;6) 0.45 3 (0;7) 0.03 −5 (−8;-2) 0.90
rs10046
AA 85 (26) 3 (−3;10) 4 (−2;10) −7 (−12;-1)
AG 173 (53) 2 (−1;7) 0.89 3 (0;7) 0.29 −6 (−9;-3) 0.06
GG 67 (21) 1 (−4;5) 3 (0;8) −3 (−7;1)
AG + GG 240 (74) 2 (−1;5) 0.64 3 (1;6) 0.22 −5 (−7;-2) 0.24
rs4646
CC 177 (54) 3 (−2;7) 4 (0;7) −4 (−8;-1)
CA 129 (40) 2 (−2;6) 0.49 3 (0;7) 0.30 −5 (−8;-2) 0.87
AA 19 (6) −6 (−18;7) 6 (−5;19) −8 (−18;4)
CA + AA 148 (46) 1 (−2;5) 0.41 3 (0;7) 0.14 −5 (−8;-2) 0.59
rs6493487
AA 192 (59) 3 (−1;8) 3 (−1;7) −5 (−9;-1)
GA 125 (39) 2 (−2;5) 0.79 4 (1;8) 0.64 −5 (−8;-2) 0.60
GG 8 (2) −1 (−11;11) −1 (−10;9) −5 (−14;5)
GA + GG 133 (41) 1 (−2;5) 0.79 4 (1;7) 0.97 −5 (−8;-2) 0.33
rs2008691
AA 210 2 (−2;6) 5 (2;8) −6 (−9;-3)
(65)
GA 106 (32) 2 (−2;6) 0.67 1 (−2;5) 0.03 −4 (−8;0) 0.41
GG 9 (3) 12 (−4;31) 10 (−3;26) 6 (−7;22)
GA + GG 115 (35) 2 (−2;7) 0.70 2 (−2;6) 0.02 −4 (−7;0) 0.31
rs3751591
TT 232 (72) 2 (−1;6) 4 (1;7) −5 (−8;-2)
TC 85 (26) 1 (−3;6) 0.78 2 (−2;6) 0.70 −5 (−8;-1) 0.90
CC 8 (2) 11 (−7;31) 9 (−6;26) 10 (−6;28)
CC vs. TT + TC 8 (2) 11 (−7;31) 0.81 9 (−6;26) 0.74 10 (−6;28) 0.86
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may indicate that the 10–20 % genetically determined
variation in sex hormone levels contributes little to BC
risk and thus, that other factors may contribute more to
hormone-dependent BC risk. These factors could be
hormone replacement therapy, child birth, and age of
menarche and menopause.
We found no evidence of interaction between genetic-
ally determined variation in aromatase and PPARγ activ-
ity. When interaction with alcohol was included in the
analysis, we found that only the PPARG Pro12Ala wild
type carriers were at significantly increased risk of BC
irrespectively of CYP19A1 genotypes. This indicates that
the effect of the PPARG Pro12Ala polymorphism is very
strong and that the CYP19A1 polymorphisms only have
minor influence on BC risk. We observed a possibly
interaction between aromatase and PGC-1α, however,
none of the PPARGC1A polymorphisms interacted with
both CYP19A1 polymorphisms and alcohol. Almost all
risk estimates were above unity indicating a strong effect
of alcohol regardless of genotype combinations. We have
previously found evidence of PPARG and PPARGC1A
being involved in alcohol-related BC [30]; however, based
on the present findings, we cannot extend this mechanism
to include aromatase. This may indicate that PPARγ medi-
ates alcohol-related BC by additional mechanisms in
addition to the one involving effects on aromatase.
We used a nested case-control design for the prospect-
ive study, which together with complete follow-up mini-
mizes selection bias. In addition, information on life style
factors was collected at enrolment, which minimizes the
risk for differential misclassification between cases and
controls. The study is fairly large to study main effects, it
is homogenous and alcohol consumption is relatively high
in the DCH cohort [70] making it suitable for studying
gene-environment interactions with alcohol. However, we
are aware that there are several limitations in studying
gene-environment interaction with NSAID use including
the limited power. The information on NSAID use re-
trieved from the FFQ may not necessarily reflect a
long-term chronic use which is considered necessary to
confer an effect on carcinogenesis [71, 72]. Moreover,
NSAID use included different types of pain killers such
as paracetamol, aspirin and Ibuprofen, which have dif-
ferent pharmacological effects and also different effect
in relation to BC risk [42]. The genes were carefully se-
lected based on their role in steroidogenesis and
alcohol-related BC. The CYP19A1 polymorphisms were
mainly tag SNPs, whereas the PPARG and PPARGC1A
polymorphisms were functional. However, only the
interaction between CYP19A1/rs4646 and PPARGC1A
Thr612Met, and the effect of CYP19A1/rs749292 on es-
trone sulphate levels withstood correction for multiple
analyses when taking the number of analysed SNPs into
account (main effects). Therefore, some of the results
based on the prospective study may be due to chance.
After acute ingestion of alcohol, estrone, estrone sulphate
and SHBG levels declined significantly and correlated
inversely with ethanol blood levels. Both controlled
acute trials [16, 20–23, 73], controlled trials with fixed
amounts of alcohol over longer periods [17, 18] and obser-
vational studies [12–15, 24, 25] have reported increased
levels of estrogens after consumption of alcohol. Most
acute studies have only measured estradiol levels, which
have been consistently increased after consumption of
alcohol [16, 19–23], whereas estrone has only been
measured in two acute studies in women using oral
contraceptives [23] and HRT [20], respectively. In the
study by Sarkola et al., estradiol increased after acute
alcohol administration, but alcohol intake had no effect
on estrone levels. However, the estradiol-to-estrone ra-
tio was significantly increased. In a study by Ginsburg
et al., estrone declined after acute alcohol consumption,
Table 3 Plasma levels of estrone, estrone sulphate and SHBG among 325 never and past users of HRT, who were also current
drinkers, as percentage difference in hormonal measurements per 10 g/day in alcohol intake (Continued)
rs2445762
TT 166 (51) 2 (−1;6) 3 (0;6) −4 (−7;-1)
TC 139 (43) 1 (−3;6) 0.94 5 (1;9) 0.19 −6 (−10;-2) 0.72
CC 20 (6) 3 (−9;16) −2 (−11;8) −8 (−17;2)
TC + CC 159 (49) 1 (−3;6) 1.00 4 (0;8) 0.17 −6 (−10;-3) 0.61
rs11070844
CC 255 (78) 1 (−2;5) 3 (0;6) −4 (−7;-1)
TC 66 (21) 5 (−1;11) 0.73 7 (1;12) 0.92 −7 (−12;-3) 0.06
TT 4 (1) 4 (−20;37) 15 (−9;45) 11 (−13;42)
TC + TT 70 (22) 5 (−1;11) 0.42 7 (2;12) 0.74 −7 (−12;-2) 0.03
SHBG Sex-hormone binding globulin
ΔPercentage difference in hormonal measurements per 10 g/day difference in alcohol intake
aAdjusted for age, smoking (never, past, current) and BMI (kg/m2) at baseline
bP-value for interaction. All interactions were kept in the models in all analyses even though there was no interaction
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Table 4 IRR for BC in relation to the studied polymorphisms among postmenopausal women in the DCH cohort
ncases (%) ncontrol (%) IRR
a (95 % CI) IRRb (95 % CI) P-valuec
(n = 687) (n = 687)
rs10519297
AA 170 (25) 174 (25) 1.00 (ref.) 1.00 (ref.)
AG 341 (50) 361 (53) 0.98 (0.76–1.27) 0.94 (0.72–1.23) 0.15
GG 176 (25) 152 (22) 1.23 (0.90–1.68) 1.25 (0.91–1.72)
AG + GG 511 (75) 513 (54) 1.05 (0.82–1.34) 1.03 (0.80–1.32) 0.83
rs749292
GG 216 (31) 203 (30) 1.00 (ref.) 1.00 (ref.)
AG 332 (48) 352 (51) 0.89 (0.69–1.14) 0.89 (0.69–1.16) 0.62
AA 139 (20) 132 (19) 0.97 (0.71–1.33) 0.99 (0.72–1.37)
AG + AA 471 (68) 484 (70) 0.91 (0.72–1.15) 0.92 (0.72–1.17) 0.50
rs1062033
CC 203 (30) 186 (27) 1.00 (ref.) 1.00 (ref.)
CG 333 (48) 354 (52) 0.85 (0.66–1.10) 0.85 (0.65–1.11) 0.46
GG 151 (22) 147 (21) 0.92 (0.67–1.25) 0.94 (0.68–1.28)
CG + GG 484 (70) 501 (73) 0.87 (0.68–1.11) 0.88 (0.68–1.12) 0.30
rs10046
AA 182 (27) 188 (28) 1.00 (ref.) 1.00 (ref.)
AG 346 (50) 353 (51) 1.02 (0.79–1.31) 0.97 (0.75–1.26) 0.52
GG 159 (23) 146 (21) 1.16 (0.85–1.57) 1.15 (0.84–1.57)
AG + GG 505 (73) 499 (72) 1.06 (0.84–1.34) 1.02 (0.80–1.31) 0.86
rs4646
CC 372 (54) 371 (54) 1.00 (ref.) 1.00 (ref.)
CA 265 (39) 262 (38) 1.00 (0.80–1.25) 0.97 (0.77–1.21) 0.95
AA 50 (7) 54 (8) 0.96 (0.63–1.45) 1.00 (0.65–1.53)
CA + AA 315 (46) 316 (46) 0.99 (0.81–1.22) 0.97 (0.78–1.20) 0.78
rs6493487
AA 407 (59) 430 (62) 1.00 (ref.) 1.00 (ref.)
GA 245 (36) 218 (32) 1.23 (0.98–1.55) 1.24 (0.98–1.58) 0.16
GG 35 (5) 39 (6) 0.96 (0.60–1.54) 0.88 (0.54–1.44)
GA + GG 280 (40) 257 (38) 1.19 (0.95–1.48) 1.18 (0.94–1.48) 0.16
rs2008691
AA 479 (70) 470 (68) 1.00 (ref.) 1.00 (ref.)
GA 179 (26) 198 (29) 0.88 (0.69–1.11) 0.88 (0.69–1.12) 0.25
GG 29 (4) 19 (3) 1.43 (0.80–2.57) 1.45 (0.80–2.64)
GA + GG 208 (30) 217 (32) 0.93 (0.74–1.17) 0.93 (0.74–1.18) 0.57
rs3751591
TT 479 (70) 498 (72) 1.00 (ref.) 1.00 (ref.)
TC 182 (26) 176 (26) 1.07 (0.84–1.36) 1.07 (0.83–1.37) 0.60
CC 26 (4) 13 (2) 2.13 (1.04–4.39) 2.12 (1.02–4.43) 0.04
TC + CC 208 (30) 189 (28) 1.13 (0.89–1.42) 1.13 (0.89–1.44) 0.31
CC vs. TT + TCd 26 (4) 13 (2) 2.09 (1.02–4.29) 2.09 (1.00–4.34) 0.05
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whereas estradiol increased. Long-term interventional
and observational studies most consistently report either
increased levels of estradiol [13, 15, 18, 25, 74–76] and/or
estrone [12, 13, 18, 75, 76] and/or estrone sulphate
[14, 17, 75] and decreased SHBG levels [12, 75–77]
among alcohol drinkers in both pre- and postmenopausal
women. However, estradiol and estrone have very short
half-lives of 35 min, whereas estrone sulphate has a half-life
of 5–7 h [17]. Therefore, only acute studies, where blood is
collected immediately after alcohol ingestion, are able to
correctly measure the effect of alcohol on estradiol and
estrone blood levels. On the other hand, acute ingestion of
alcohol may have different effects on sex-steroids than
chronic alcohol consumption, as illustrated by studies on
alcohol consumption and immune effects [78]. It has been
suggested that acute ingestion of alcohol affects catabolism
of the hormones in the liver rather than synthesis [22, 23,
79, 80]. In the liver, alcohol consumption increases the
[NADH]: [NAD+] ratio which leads to a decreased catabol-
ism of sex-hormones mediated by 17β-hydroxysteroid de-
hydrogenase type 2 enzyme resulting in increased levels of
testosterone and estradiol and decreased levels of andro-
stenedione and estrone. Furthermore, it has been shown
that only long-term chronic ingestion of alcohol induces
Table 4 IRR for BC in relation to the studied polymorphisms among postmenopausal women in the DCH cohort (Continued)
rs2445762
TT 359 (52) 365 (53) 1.00 (ref.) 1.00 (ref.)
TC 278 (40) 276 (40) 1.02 (0.81–1.27) 1.04 (0.83–1.31) 0.74
CC 50 (8) 46 (7) 1.10 (0.72–1.69) 1.19 (0.76–1.85)
TC + CC 328 (48) 322 (47) 1.03 (0.83–1.27) 1.06 (0.85–1.32) 0.61
rs11070844
CC 552 (80) 556 (81) 1.00 (ref.) 1.00 (ref.)
TC 129 (19) 125 (18) 1.06 (0.801–1.39) 1.06 (0.80–1.40) 0.88
TT 6 (1) 6 (1) 1.01 (0.33–3.13) 0.86 (0.27–2.73)
TC + TT 135 (20) 131 (19) 1.06 (0.81–1.38) 1.05 (0.80–1.38) 0.73
aCrude
bAdjusted for parous/nulliparous, number of births, age at first birth, length of school education (low, medium, high), duration of HRT use (years), BMI (kg/m2) and
alcohol intake (10 g/day)
cP-value for trend
dCC versus TT and TC
Table 5 Baseline characteristics of the RTC study participants
Characteristic PPARγ2 Pro12 (n = 18) PPARγ2 12Ala (n = 7) P-valuesd
Median Range Median Range
Agea, years 58.5 (49–70) 55 (47–67) 0.28
Weight, kg 64.1 (50.1–86.5) 59.8 (57.2–68.4) 0.27
BMI, kg/m2 23.5 (19.1–26.9) 22.4 (19.4–24.5) 0.14
Years since last menses 5.5 (1–25) 6 (3–16) 0.46
Alcohol intake/week 6.5 (1–15) 6 (3.5–14) 0.70
Characteristic PPARγ2 Pro12 (n = 18) PPARγ2 12Ala (n = 7)
No. % No. %
Menopause type
Naturalb 17 94.4 6 85.7
Hysterectomyc 1 6.6 1 14.3
Smoking status
Never 10 55.6 5 71.4
Former 8 44.4 2 28.6
Characteristics of participants from the RCT divided by genotype
aOne participant was only 48 years, but had not had her menses for 6 years. All other participants were older than 50 years
bOne participant had had a unilateral oophorectomy
cOne participant had a combined hysterectomy and oophorectomy; and one participant had a hysterectomy before last menses, but was older than 60 years
dP-values for comparison of baseline characteristics using Student’s t-test
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aromatase [22, 34]. We detected a decline in estrone
sulphate levels shortly after ingestion of alcohol, supporting
that acute alcohol intake affects metabolism of female sex-
hormone, which may explain the discrepancies between re-
sults from observational and experimental studies.
The RCT also has several limitations. Our aim was to
conduct a pilot study to examine whether the PPARG
Pro12Ala polymorphisms had any influence on the blood
hormone level after consumption of alcohol with and
without concurrent intake of Ibuprofen. Based on a con-
trolled long-term feeding study [17], we should have an
80 % chance of detecting a change in hormone levels of
10 % on a 5 % significance level (α = 0.05) with 11 partici-
pants in each group. However, we were only able to recruit
7 PPARG 12Ala variant-carriers. Nevertheless, we found sta-
tistically significant decreases in estrone, estrone sulphate
and SHBG levels. We did not include an alcohol placebo
group because our main aim was to examine the effect of
concurrent use of Ibuprofen and alcohol consumption on
circulating hormone levels. Therefore, the hormone effect
could potentially be an effect of the ingredients in the alco-
holic drink. However, other interventional studies have
used similar ingredients in the alcoholic test drink e.g. dif-
ferent types of fruit juices [17, 18, 20, 22, 23, 73, 81] or pure
glucose [16] without an effect on hormone levels. In order
to verify the results from the present study, a new study
should preferably include a placebo group, and if feasible
for ethical reasons should also assess effects over a longer
exposure period. Moreover, other steroid hormones should
be included to examine other effects of alcohol consump-
tion on steroidogenesis and metabolism. The method used
to measure hormones differs from all the other studies
mentioned in this paper. We determined the hormones by
LC-MS because of its documented specificity [82] and to
avoid overestimation due to lack of specificity of antibodies,
which is a well-known challenge with conventional radio-
immunoassays [82, 83]. However, MS methods suffer from
lack of sensitivity and, consequently, we were not able to in-
clude results on estradiol measurements and 11 % of the
estrone measurements had levels below zero which further
decreased the statistical power.
Conclusion
Our results show that alcohol consumption and inherent
variations in CYP19A1 influence the level of circulating
blood sex-hormones. Specifically, CYP19A1/rs1062033
was associated to both estrone sulphate levels and to
alcohol-dependent differences in estrone sulphate levels.
CYP19A1/rs3751591 was both associated with SHBG
Fig. 4 Estrone concentrations as a function of time. Zero values
have been replaced by half of the Limit of Detection = 0.5 pmol/L.
Values represent pooled mean measurements ± SEM (n = 50). Ptime
(0-90min) = <0.0001; Ptime (0-1200min) = 0.02
Fig. 5 SHBG concentrations as a function of time. Values represent
pooled mean measurements ± SEM (n = 50). Ptime (0-90min) = 0.009
Fig. 6 Estrone sulphate concentrations as a function of time. Values
represent pooled mean measurements ± SEM (n = 50).
Ptime (0-90min) = <0.0001
Fig. 7 Ethanol concentrations as a function of time. Values represent
pooled mean measurements ± SEM (n = 50). Ptime (0-90min) = <0.0001
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levels and with risk of BC such that homozygous variant
allele carriers had increased levels of serum SHBG and
were at increased risk of BC. However, the genetically
determined differences in sex hormone levels were not
convincingly associated with BC risk. The results there-
fore indicate that the genetically determined variation in
sex-hormone levels contributes little to BC risk and thus,
that other factors may contribute more to hormone-
dependent BC risk. In addition, our results indicate that
acute and chronic alcohol consumption may affect metab-
olism and biosynthesis of estrogens differently. We were
unable to show that aromatase is part of the mechanism
of PPARγ-dependent alcohol-related BC.
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